Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Newsam
John M. Newsam, La Jolla, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20110028460 | TOPICAL FORMULATION - It has been discovered that certain combinations compounds are excellent penetration enhancers and, as such, can be incorporated in a topical formulation to facilitate administration of active agents. The increased penetration enhancement can also lead to a reduction in the total concentration of skin irritants in the formulation. There is described herein a topical formulation comprising (i) at least one active agent; (ii) a first compound, and (iii) a second compound, wherein the first compound and second compound are different, and each is selected from the group consisting of N-lauroyl sarcosine, sodium octyl sulfate, methyl laurate, isopropyl myristate, oleic acid, glyceryl oleate and sodium lauryl sulfoacetate. | 02-03-2011 |
John M. Newsam, San Diego, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20080221212 | TOPICAL FORMULATION - There is described a topical formulation. The topical formulation includes: (i) diclofenac or a pharmaceutically acceptable salt thereof, (ii) a first compound, and (iii) a second compound. The first compound and second compound are different, and each is selected from the group consisting essentially of N-lauroyl sarcosine, sodium octyl sulfate, methyl laurate, isopropyl myristate, oleic acid, glyceryl oleate and sodium lauryl sulfoacetate. It has been discovered that certain combination of compounds are excellent penetration enhancers and, as such, can be incorporated in a topical formulation to facilitate administration of diclofenac or a pharmaceutically acceptable salt thereof. The increased penetration enhancement can also lead to a reduction in the total concentration of skin irritants in the formulation. | 09-11-2008 |
| 20100029769 | TOPICAL FORMULATION - There is described a topical formulation. The topical formulation comprises: (i) diclofenac or a pharmaceutically acceptable salt thereof, (ii) a first compound, and (iii) a second compound. The first compound and second compound are different, and each is selected from the group consisting essentially of N-lauroyl sarcosine, sodium octyl sulfate, methyl laurate, isopropyl myristate, oleic acid, glyceryl oleate and sodium lauryl sulfoacetate. It has been discovered that certain combination of compounds are excellent penetration enhancers and, as such, can be incorporated in a topical formulation to facilitate administration of diclofenac or a pharmaceutically acceptable salt thereof. The increased penetration enhancement can also lead to a reduction in the total concentration of skin irritants in the formulation. | 02-04-2010 |
Mark Ian Newsam, Peebles GB
| Patent application number | Description | Published |
|---|---|---|
| 20110096239 | Temporary Memory Circuits for Matrix Display Device - A circuit for supplying video data supplied in frames divided into timeslots to an array of pixels comprises a plurality of one-bit temporary storage elements (M), at least some of which are arranged to store data for different pixels of the array during different timeslots within a frame. The circuit can be used in an electroluminescent display in which each pixel (P) comprises an organic light-emitting diode. | 04-28-2011 |
Shawn Newsam, Merced, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20090081721 | HIGH-THROUGHPUT CELL ASSAYS - This invention provides high-through put methods and systems to identify and/or classify cells present in a sample. In one aspect, the method identifies the cell by determining the amount of thermal energy required to disrupt cell membranes. In another aspect, a method is for determining if an agent such as a drug will inhibit the growth of a cell by monitoring the amount of energy required to maintain a substantially constant temperature in a sample containing the cell grown in the presence of an agent or drug is provided. | 03-26-2009 |